Compare GSK plc (GSK) vs Monster Beverage Corp (MNST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Monster Beverage Corp — how do they compare? GSK plc trades at $52.85 (market cap $101.34B), while Monster Beverage Corp trades at $98.18 (market cap $95.42B). The key difference: GSK plc and Monster Beverage Corp are close in size by market cap, and GSK plc pays a 3.49% dividend while Monster Beverage Corp pays none. Which is the better fit depends on your goals.
| GSK | MNST | |
|---|---|---|
Market Cap | $101.34B | $95.42B |
Sector | Health | Consumer Staples |
52-Week High | $61.18 | $98.01 |
52-Week Low | $36.20 | $58.65 |
Enterprise Value | $121.95B | $93.72B |
Dividend Yield | 3.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
Monster Beverage (MNST) trades at $98.46, up 0.46% on the day, with a bullish technical outlook supported by moving averages and recent earnings beats. The company reported strong fundamentals with 2025 revenue of $8.29 billion, net income of $1.91 billion, and a 23.11% net margin. A 2-for-1 stock split announced for August 2026 reflects confidence in growth, while analyst sentiment remains positive with 53% buy ratings.
MNST's premium valuation (P/E 47.14) is justified by robust profitability and international expansion, but high multiples pose sensitivity to earnings misses. Risks include competitive pressures and economic headwinds. The consensus price target of $94.60 suggests near-term consolidation, though continued execution could drive upside toward the $113 high target.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Monster Beverage Corp
Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.
Read more on MNST →
